JO3509B1 - معدلات p2x7 - Google Patents

معدلات p2x7

Info

Publication number
JO3509B1
JO3509B1 JOP/2014/0096A JOP20140096A JO3509B1 JO 3509 B1 JO3509 B1 JO 3509B1 JO P20140096 A JOP20140096 A JO P20140096A JO 3509 B1 JO3509 B1 JO 3509B1
Authority
JO
Jordan
Prior art keywords
pyridinyl
phenyl
formula
pyradizinyl
thiophenyl
Prior art date
Application number
JOP/2014/0096A
Other languages
English (en)
Inventor
A Rudolph Dale
A Letavic Michael
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3509B1 publication Critical patent/JO3509B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يوجه هذا الاختراع بصفة عامة إلى مركب بالصيغة (I)، الصيغة (I) حيث: n هو عدد صحيح من 0-1؛ X يمثل الميثيلين إذا كان n يساوي 0، أو X يمثل الميثيلين أو الأكسيجين إذا كان n يساوي 1؛ R1 هو الفينيل أو البيريدينيل، حيث يستبدل الفينيل أو البيريدينيل اختياريًا بهالوجين أو ألكيل؛ و R2 هو الفينيل أو البيريدينيل أو البيرازينيل أو البيريميدينيل أو البيروليل أو البيرازوليل أو الثيازوليل أو الثيوفينيل، حيث يستبدل الفينيل أو البيريدينيل أو البيرازينيل أو البيريميدينيل أو البيروليل أو البيرازوليل أو الثيازوليل أو الثيوفينيل اختياريًا بهالوجين أو ألكيل أو هيدروكسي أو ألكوكسي. كما يتعلق الاختراع أيضاً بتركيبات دوائية تتألف من مركبات الصيغة (I). كما تقع أيضًا طرق تحضير مركبات الصيغة (I) واستخدامها ضمن نطاق الاختراع.
JOP/2014/0096A 2013-03-14 2014-03-12 معدلات p2x7 JO3509B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785558P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
JO3509B1 true JO3509B1 (ar) 2020-07-05

Family

ID=50631041

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0096A JO3509B1 (ar) 2013-03-14 2014-03-12 معدلات p2x7

Country Status (9)

Country Link
US (3) US9102686B2 (ar)
EP (2) EP2970287B1 (ar)
JP (1) JP6294954B2 (ar)
AR (1) AR095421A1 (ar)
ES (2) ES2652648T3 (ar)
JO (1) JO3509B1 (ar)
TW (1) TWI627174B (ar)
UY (1) UY35447A (ar)
WO (1) WO2014152621A1 (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
TWI627174B (zh) * 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JP6625616B2 (ja) 2014-09-12 2019-12-25 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節ｎ−アシル−トリアゾロピラジン
WO2016039977A1 (en) * 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
EP3287443B1 (en) 2015-04-24 2021-10-27 Shionogi & Co., Ltd 6-membered heterocyclic derivative and pharmaceutical composition comprising same
WO2017040764A1 (en) * 2015-09-04 2017-03-09 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof
CN105596301A (zh) * 2016-01-29 2016-05-25 中国药科大学 一种以异喹啉为基本骨架的p2x7受体拮抗剂的纳米混悬剂及其制备方法
CN105503884B (zh) * 2016-02-17 2017-10-13 上海皓元生物医药科技有限公司 一种用于合成bet蛋白抑制剂的关键中间体的合成方法
WO2018074390A1 (ja) * 2016-10-17 2018-04-26 塩野義製薬株式会社 二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
AU2020358948A1 (en) 2019-09-30 2022-05-26 Janssen Pharmaceutica Nv Radiolabelled MGL PET ligands
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US905687A (en) 1908-07-14 1908-12-01 Samuel W Evans Jr Folding umbrella and cane.
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA2093125C (en) 1990-10-02 2003-12-16 Warner-Lambert Company Angiotensin ii antagonists
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
CA2493625A1 (en) 2002-07-25 2004-02-19 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
CA2576465A1 (en) 2004-08-23 2006-03-02 Merck & Co., Inc. Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2008528580A (ja) 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
JP2010530427A (ja) 2007-06-21 2010-09-09 シェーリング コーポレイション 多環式グアニン誘導体およびその使用方法
SG183699A1 (en) 2007-08-10 2012-09-27 Lundbeck & Co As H Heteroaryl amide analogues
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
KR101598397B1 (ko) 2008-04-22 2016-02-29 얀센 파마슈티카 엔.브이. 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
JP5063815B2 (ja) 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
US8501946B2 (en) * 2009-04-29 2013-08-06 Glaxo Group Limited 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
EP2552920B1 (en) 2010-04-02 2017-03-15 Ogeda Sa Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
WO2011128769A2 (en) 2010-04-16 2011-10-20 Rodrigo Graf Fernandez Foldable structures for a construction
WO2012040048A2 (en) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones as p2x7 receptor antagonists
BR112014029161A2 (pt) 2012-05-22 2017-06-27 Genentech Inc benzamidas n-substituídas e seu uso no tratamento de dor
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN105102432B (zh) 2012-10-15 2019-01-04 Epizyme股份有限公司 经取代的苯化合物
JP6466335B2 (ja) 2012-10-16 2019-02-06 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲ−γ−Ｔのメチレン連結キノリニルモジュレーター
JP6359546B2 (ja) 2012-11-01 2018-07-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
CA2895808A1 (en) 2012-12-21 2014-06-26 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
SMT201800230T1 (it) 2012-12-21 2018-07-17 Plexxikon Inc Composti e metodi per la modulazione della chinasi e loro indicazioni
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
RS59909B1 (sr) 2013-03-06 2020-03-31 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
EA201591610A1 (ru) 2013-03-14 2015-12-30 Курадев Фарма Прайвит Лтд. Ингибиторы кинуренинового пути
ES2704048T3 (es) 2013-03-14 2019-03-14 Glaxosmithkline Ip No 2 Ltd Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina-2,3-disustituida y su uso como inhibidores de bromodominio
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
PE20151593A1 (es) 2013-03-14 2015-11-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CA2907814C (en) 2013-03-29 2021-07-13 Euroscreen Sa Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
JP6625616B2 (ja) 2014-09-12 2019-12-25 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節ｎ−アシル−トリアゾロピラジン
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators

Also Published As

Publication number Publication date
JP2016513702A (ja) 2016-05-16
ES2776654T3 (es) 2020-07-31
TWI627174B (zh) 2018-06-21
HK1218649A1 (en) 2017-03-03
US9540388B2 (en) 2017-01-10
EP2970287B1 (en) 2017-11-01
US10053462B2 (en) 2018-08-21
US20170088550A1 (en) 2017-03-30
UY35447A (es) 2014-09-30
US9102686B2 (en) 2015-08-11
AR095421A1 (es) 2015-10-14
US20140275056A1 (en) 2014-09-18
HK1254111A1 (en) 2019-07-12
JP6294954B2 (ja) 2018-03-14
EP2970287A1 (en) 2016-01-20
EP3309161B1 (en) 2019-12-18
ES2652648T3 (es) 2018-02-05
US20160039836A1 (en) 2016-02-11
EP3309161A1 (en) 2018-04-18
WO2014152621A1 (en) 2014-09-25
TW201522339A (zh) 2015-06-16

Similar Documents

Publication Publication Date Title
SA515361086B1 (ar) Fasn مركبات وتركيبات جديدة لتثبيط
AR095421A1 (es) Moduladores de p2x7
EP4272824A3 (en) Substituted 2-azabicycles and their use as orexin receptor modulators
UA118549C2 (uk) 2,3-дизаміщені похідні 1-ацил-4-аміно-1,2,3,4-тетрагідрохіноліну та їх застосування як інгібіторів бромодомену
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
MX347459B (es) Nuevos compuestos y composiciones para la inhibición de nampt.
PH12015502030A1 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
IN2014CN01024A (ar)
MY169267A (en) New aryl-quinoline derivatives
MY161134A (en) Piperazine compound having a pgds inhibitory effect
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
PH12015500654A1 (en) Pest controlling composition and use thereof
PL401473A1 (pl) Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania
MX2015016400A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
MX2016007985A (es) Compuestos de fluorofenilpirazol.
MX2015015058A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
SA519400868B1 (ar) معدلات عطرية غير متجانسة لأشعة جاما لمستقبل يتيم ذي علاقة بريتينويد
CO6660459A2 (es) Derivados de 4-(metilaminofenoxi)piridin-3-il-benzamina para tratar cancer
IN2015DN02514A (ar)
LV14984A (lv) 2-Fenilamino-4-(piridīn-3-il)-6-perfluoralkilpirimidīni
IN2013MU01256A (ar)
GB201013509D0 (en) Compounds
NZ751449A (en) Novel compounds and compositions for inhibition of fasn
UA70747U (ru) Тиосемикарбазоны 1,2-дизамещенных 4-хлороимидазол-5-карбальдегидов, проявляющие противотуберкулезную активность